Cargando…

Monoglyceride lipase deficiency causes desensitization of intestinal cannabinoid receptor type 1 and increased colonic μ-opioid receptor sensitivity

BACKGROUND AND PURPOSE: Monoglyceride lipase (MGL) degrades 2-arachidonoyl glycerol (2-AG), an endogenous agonist of cannabinoid receptors (CB(1/2)). Because the CB(1) receptor is involved in the control of gut function, we investigated the effects of pharmacological inhibition and genetic deletion...

Descripción completa

Detalles Bibliográficos
Autores principales: Taschler, U, Eichmann, T O, Radner, F P W, Grabner, G F, Wolinski, H, Storr, M, Lass, A, Schicho, R, Zimmermann, R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Ltd 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4556478/
https://www.ncbi.nlm.nih.gov/pubmed/26075589
http://dx.doi.org/10.1111/bph.13224
_version_ 1782388353346306048
author Taschler, U
Eichmann, T O
Radner, F P W
Grabner, G F
Wolinski, H
Storr, M
Lass, A
Schicho, R
Zimmermann, R
author_facet Taschler, U
Eichmann, T O
Radner, F P W
Grabner, G F
Wolinski, H
Storr, M
Lass, A
Schicho, R
Zimmermann, R
author_sort Taschler, U
collection PubMed
description BACKGROUND AND PURPOSE: Monoglyceride lipase (MGL) degrades 2-arachidonoyl glycerol (2-AG), an endogenous agonist of cannabinoid receptors (CB(1/2)). Because the CB(1) receptor is involved in the control of gut function, we investigated the effects of pharmacological inhibition and genetic deletion of MGL on intestinal motility. Furthermore, we determined whether defective 2-AG degradation affects μ-opioid receptor (μ receptor) signalling, a parallel pathway regulating gut motility. EXPERIMENTAL APPROACH: Gut motility was investigated by monitoring Evans Blue transit and colonic bead propulsion in response to MGL inhibition and CB(1) receptor or μ receptor stimulation. Ileal contractility was investigated by electrical field stimulation. CB(1) receptor expression in ileum and colon was assessed by immunohistochemical analyses. KEY RESULTS: Pharmacological inhibition of MGL slowed down whole gut transit in a CB(1) receptor-dependent manner. Conversely, genetic deletion of MGL did not affect gut transit despite increased 2-AG levels. Notably, MGL deficiency caused complete insensitivity to CB(1) receptor agonist-mediated inhibition of whole gut transit and ileal contractility suggesting local desensitization of CB(1) receptors. Accordingly, immunohistochemical analyses of myenteric ganglia of MGL-deficient mice revealed that CB(1) receptors were trapped in endocytic vesicles. Finally, MGL-deficient mice displayed accelerated colonic propulsion and were hypersensitive to μ receptor agonist-mediated inhibition of colonic motility. This phenotype was reproduced by chronic pharmacological inhibition of MGL. CONCLUSION AND IMPLICATIONS: Constantly elevated 2-AG levels induce severe desensitization of intestinal CB(1) receptors and increased sensitivity to μ receptor-mediated inhibition of colonic motility. These changes should be considered when cannabinoid-based drugs are used in the therapy of gastrointestinal diseases.
format Online
Article
Text
id pubmed-4556478
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher John Wiley & Sons, Ltd
record_format MEDLINE/PubMed
spelling pubmed-45564782015-10-14 Monoglyceride lipase deficiency causes desensitization of intestinal cannabinoid receptor type 1 and increased colonic μ-opioid receptor sensitivity Taschler, U Eichmann, T O Radner, F P W Grabner, G F Wolinski, H Storr, M Lass, A Schicho, R Zimmermann, R Br J Pharmacol Research Papers BACKGROUND AND PURPOSE: Monoglyceride lipase (MGL) degrades 2-arachidonoyl glycerol (2-AG), an endogenous agonist of cannabinoid receptors (CB(1/2)). Because the CB(1) receptor is involved in the control of gut function, we investigated the effects of pharmacological inhibition and genetic deletion of MGL on intestinal motility. Furthermore, we determined whether defective 2-AG degradation affects μ-opioid receptor (μ receptor) signalling, a parallel pathway regulating gut motility. EXPERIMENTAL APPROACH: Gut motility was investigated by monitoring Evans Blue transit and colonic bead propulsion in response to MGL inhibition and CB(1) receptor or μ receptor stimulation. Ileal contractility was investigated by electrical field stimulation. CB(1) receptor expression in ileum and colon was assessed by immunohistochemical analyses. KEY RESULTS: Pharmacological inhibition of MGL slowed down whole gut transit in a CB(1) receptor-dependent manner. Conversely, genetic deletion of MGL did not affect gut transit despite increased 2-AG levels. Notably, MGL deficiency caused complete insensitivity to CB(1) receptor agonist-mediated inhibition of whole gut transit and ileal contractility suggesting local desensitization of CB(1) receptors. Accordingly, immunohistochemical analyses of myenteric ganglia of MGL-deficient mice revealed that CB(1) receptors were trapped in endocytic vesicles. Finally, MGL-deficient mice displayed accelerated colonic propulsion and were hypersensitive to μ receptor agonist-mediated inhibition of colonic motility. This phenotype was reproduced by chronic pharmacological inhibition of MGL. CONCLUSION AND IMPLICATIONS: Constantly elevated 2-AG levels induce severe desensitization of intestinal CB(1) receptors and increased sensitivity to μ receptor-mediated inhibition of colonic motility. These changes should be considered when cannabinoid-based drugs are used in the therapy of gastrointestinal diseases. John Wiley & Sons, Ltd 2015-09 2015-07-30 /pmc/articles/PMC4556478/ /pubmed/26075589 http://dx.doi.org/10.1111/bph.13224 Text en © 2015 The British Pharmacological Society
spellingShingle Research Papers
Taschler, U
Eichmann, T O
Radner, F P W
Grabner, G F
Wolinski, H
Storr, M
Lass, A
Schicho, R
Zimmermann, R
Monoglyceride lipase deficiency causes desensitization of intestinal cannabinoid receptor type 1 and increased colonic μ-opioid receptor sensitivity
title Monoglyceride lipase deficiency causes desensitization of intestinal cannabinoid receptor type 1 and increased colonic μ-opioid receptor sensitivity
title_full Monoglyceride lipase deficiency causes desensitization of intestinal cannabinoid receptor type 1 and increased colonic μ-opioid receptor sensitivity
title_fullStr Monoglyceride lipase deficiency causes desensitization of intestinal cannabinoid receptor type 1 and increased colonic μ-opioid receptor sensitivity
title_full_unstemmed Monoglyceride lipase deficiency causes desensitization of intestinal cannabinoid receptor type 1 and increased colonic μ-opioid receptor sensitivity
title_short Monoglyceride lipase deficiency causes desensitization of intestinal cannabinoid receptor type 1 and increased colonic μ-opioid receptor sensitivity
title_sort monoglyceride lipase deficiency causes desensitization of intestinal cannabinoid receptor type 1 and increased colonic μ-opioid receptor sensitivity
topic Research Papers
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4556478/
https://www.ncbi.nlm.nih.gov/pubmed/26075589
http://dx.doi.org/10.1111/bph.13224
work_keys_str_mv AT taschleru monoglyceridelipasedeficiencycausesdesensitizationofintestinalcannabinoidreceptortype1andincreasedcolonicmopioidreceptorsensitivity
AT eichmannto monoglyceridelipasedeficiencycausesdesensitizationofintestinalcannabinoidreceptortype1andincreasedcolonicmopioidreceptorsensitivity
AT radnerfpw monoglyceridelipasedeficiencycausesdesensitizationofintestinalcannabinoidreceptortype1andincreasedcolonicmopioidreceptorsensitivity
AT grabnergf monoglyceridelipasedeficiencycausesdesensitizationofintestinalcannabinoidreceptortype1andincreasedcolonicmopioidreceptorsensitivity
AT wolinskih monoglyceridelipasedeficiencycausesdesensitizationofintestinalcannabinoidreceptortype1andincreasedcolonicmopioidreceptorsensitivity
AT storrm monoglyceridelipasedeficiencycausesdesensitizationofintestinalcannabinoidreceptortype1andincreasedcolonicmopioidreceptorsensitivity
AT lassa monoglyceridelipasedeficiencycausesdesensitizationofintestinalcannabinoidreceptortype1andincreasedcolonicmopioidreceptorsensitivity
AT schichor monoglyceridelipasedeficiencycausesdesensitizationofintestinalcannabinoidreceptortype1andincreasedcolonicmopioidreceptorsensitivity
AT zimmermannr monoglyceridelipasedeficiencycausesdesensitizationofintestinalcannabinoidreceptortype1andincreasedcolonicmopioidreceptorsensitivity